February 2, 2018

February 02, 2018

Miss Tampa pageant sponsor celebrates 25 years of successful winners

Tampa Bay Times – Feb. 2
She serves as a clinical trials infusion nurse at the Miami Cancer Institute where she helps with clinical trial research. Although having recently moved from the Tampa area, she credits being able to network with others at the Moffitt Cancer Center when she was Miss Tampa for her current success.

Edgerrin James: From Hall of Fame-worthy career to ‘Sugar Dad’

WXIN – Feb. 2
Along with the tug of his kids, he was committed to helping Andia Wilson, his high school sweetheart and mother of four of his children, through her battle with leukemia. When his schedule with the Cardinals allowed, he returned to Tampa to be by her side at the Moffitt Cancer Center. 

Locke Highlights Axi-Cel/Atezolizumab Data in DLBCL

OncLive – Feb. 1
In an interview with OncLive, Locke, a medical oncologist at Moffitt Cancer Center, discussed the initial data for axi-cel plus atezolizumab in DLBCL and reflected on the long-term survival data from the ZUMA-1 trial.

Owner of Little Greek chain finally meets bone marrow donor who saved his life

Tampa Bay Times – Feb. 1
On Jan. 20, 2017, Vojnovic, the 58-year-old owner of the Little Greek Fresh Grill chain, laid in a hospital bed at Moffitt Cancer Center and watched this stranger’s stem cells flow through a tube into his veins.

A new treatment aims to prevent hair loss in cancer patients

CNBC – Feb. 1
Today, DigniCap is available in 125 treatment facilities in the United States — including 10 of the 13 National Cancer Institute Cancer Centers — and the Paxman device is available in 70 facilities, with each adding new ones rapidly. Memorial Sloan Kettering in New York City; Moffitt Cancer Center in Tampa; the Dana Farber Cancer Institute in Boston and the Rocky Mountain Cancer Center in Boulder, Colorado, all carry some form of approved scalp-cooling device.

OncLive to Host Latest State of the Science Summit: Gastrointestinal Malignancies

BioSpace – Feb. 1
The program will feature renowned oncologists who will be joined by program chair, John Marshall, M.D., chief, division of hematology/oncology; MedStar Georgetown University Hospital; professor of medicine and oncology, Lombardi Comprehensive Cancer Center, Georgetown University; and director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer. Joining Marshall:

  • Jonathan Strosberg, M.D., associate professor, H. Lee Moffitt Cancer Center

FDA Approves Lutathera for Gastroenteropancreatic Neuroendocrine Tumors

Cancer Network – Feb. 1
“There are very few effective treatment options for patients with inoperable, advanced GEP-NETs who are progressive on somatostatin analogues,” said Jonathan Strosberg, MD, section head of the Neuroendocrine Tumor Program at Moffitt Cancer Center in Tampa, Florida, and NETTER-1 lead investigator, in a press release. “As a medical oncologist seeing more than 500 patients with NETs each year, I am grateful to have another tool in my arsenal.”

Rays top prospects of all-time: No. 7

DRays Bay – Feb. 1
It was the second time he was the Rays’ nominee. According to the press release accompanying his nomination, Longoria and his wife are involved in numerous charities, including the Rays Baseball Foundation, Moffitt Cancer Center, and Suncoast Credit Union’s “Reading with the Rays” initiative, among others.

11th-Annual Spring Swing® - Moffitt’s Sun Safety Tour Hits Florida Ballparks With Free Screenings

Public Now – Feb. 1
Spring Swing® - Moffitt's Sun Safety Tour is a partnership between Moffitt and the Tampa Bay Rays offering free skin cancer screenings at specified baseball spring training venues throughout Florida. Screeners look for early signs of skin cancer while promoting sun safety, skin cancer awareness and education with help from Moffitt's Mole Patrol® team. 

Bay area cancer survivor meets bone marrow donor for the first time

WTSP – Jan. 31
With her donation and the support of many OneBlood platelet and blood donors, Vojnovic underwent his transplant at Moffitt Cancer Center in January 2017 and won his battle to live.  Out of 29 million people, Gomez was the only match.

Dense Tissue Is Not an Obstacle to Immunotherapy in Desmoplastic Melanoma

Oncology Nursing News – Jan. 31
A small but powerful study by a team of scientists from 10 different cancer centers around the globe – including Moffitt Cancer Center and UCLA – assessed 60 adults with advanced desmoplastic melanoma who received either pembrolizumab (Keytruda) or nivolumab (Opdivo).

Forty years after starting business in Bradenton, he’s ready to call it a career

Bradenton Herald – Jan. 31
“Since starting the tournament, we have given over a million dollars to cancer research via Golfers Against Cancer. Most of that has ended up at Moffitt Cancer Center in Tampa,” Jane Trinci said.

Researchers discover new approach to stimulate an immune response against tumour cells

eCancer.org – Jan. 31
A team of Moffitt Cancer Center researchers is trying to find new ways to further enhance the activity of the immune system against cancer.

LUNGevity Foundation Announces Initiative to Save Lives Through Increased Adherence to Lung Cancer Screening

Marketplace.org – Jan. 31
The project is a collaborative effort between LUNGevity Foundation and health psychologist Dr. Jamie Studts from University of Kentucky Markey Cancer Center and health economist Dr. Margaret Byrne from Moffitt Cancer Center in Tampa, FL.

7 things to know today and Florida Hospital no longer seeks Sanford Burnham assets

Orlando Business Journal – Jan. 31
Florida Hospital, which would have teamed up with Tampa's H. Lee Moffitt Cancer Center, wanted to transform the 175,000-square-foot facility into a National Cancer Institute-designated comprehensive cancer center, which would be a first in Central Florida, and create hundreds of high-wage jobs. Read the full story here.

The Use And Sequencing Of Tyrosine Kinase Inhibitors (TKI’s) In Hepatocellular Carcinoma (HCC)

Oncology Tube – Jan. 30
Only one TKI is approved in a first line setting. Joining us from the 2018 Gastrointestinal Cancers Symposium is Dr. Richard Kim, MD, Gastrointestinal Oncology Department, Moffitt Cancer Center, Assistant Professor of Oncology, University of South Florida College of Medicine, describes the different TKI's and their uses and also the status of sequencing them.

The Surveillance And The Management Of Gastroesophageal Cancer

Oncology Tube – Jan. 30
Dr. Khaldoun Almhanna, MD, MPH, Department of Gastrointestinal Oncology, Moffitt Cancer Center, Associate Professor of Oncology, University of South Florida College, talks about the current state of gastroesophageal cancer screening and describes it’s use within the United States, here at the 2018 Gastrointestinal Cancers Symposium.

Florida Hospital pulls its Sanford Burnham offer

Orlando Sentinel – Jan. 30
In its proposal, Florida Hospital was the main funder, investing $100 million over 10 years, and was planning to bring in its partner, Moffitt Cancer Center in Tampa, to establish a cancer research and treatment center.

Researchers discover new approach to stimulate an immune response against tumor cells

Medical Xpress – Jan. 30
A team of Moffitt Cancer Center researchers is trying to find new ways to further enhance the activity of the immune system against cancer. 

How Moffitt helped develop a drug to treat the kind of cancer that killed Steve Jobs

Tampa Bay Business Journal – Jan. 29
A Moffitt Cancer Center physician was the lead investigator in a clinical trial for a just-approved drug to treat a type of cancer that affects the pancreas or gastrointestinal tract.

Acute Lymphoblastic Leukemia: Risk Stratification

OncLive – Jan. 29
Bijal D. Shah, MD:  I think what we’re seeing more and more, particularly in our young adult population, is a high frequency of Ph-like abnormalities, which we define as rearrangements of CRLF2 and JAK2 predominantly.

Bou Zgheib to serve as chair of robotics committee

The Huntington WV Herald-Dispatch – Jan. 29
Bou Zgheib completed fellowship training in clinical and research gynecologic oncology at the Moffitt Cancer Center at the University of South Florida. He also underwent advanced surgical training for gynecologic malignancies and special pelvic procedures at the Center for Advanced Medical Learning and Simulation in Tampa, Florida.

Bevacizumab dramatically improves severe hereditary hemorrhagic telangiectasia (HHT) associated bleeding

BrightSurf.com – Jan. 29
Moffitt Cancer Center will present preliminary results from a phase 1 study testing whether the addition of pembrolizumab to radiation therapy and bevacizumab is safe and can control tumor growth for these patients.

Blood Cancer Survivor To Meet Stem Cell Transplant Donor

Tampa Bay Newswire – Jan. 29
Luckily, an unrelated donor match who joined the registry during college was found and with her donation and the support of many OneBlood platelet and blood donors, Nick underwent his transplant at Moffitt Cancer Center in January 2017 and won his battle to live!  A surprise meeting between Nick and his stem cell donor Caroline has been arranged.

AutoNation's ties to cancer centers helps its employees

AutoNews - Jan. 29
AutoNation executives called the Moffitt Cancer Center in Tampa, Fla. Because of the company's contributions to the center, Moffitt took the employee's daughter the next day and gave her another treatment option.

There is no good cancer


Citrus County Chronicle – Jan. 28
Finally, in September she heard the words she was dreading: “You have cancer.” Or, as one doctor from Moffitt Cancer Center said, “That’s a big, freakin’ tumor.”

Advanced Accelerator Applications Receives US FDA Approval for LUTATHERA for Treatment of Gastroenteropancreatic Neuroendocrine Tumors

Pharmacy Choice – Jan. 27
Jonathan Strosberg, MD, Associate Professor, Section Head, Neuroendocrine Tumor Program at Moffitt Cancer Center, and NETTER-1 lead investigator, commented There are very few effective treatment options for patients with inoperable, advanced GEP-NETs who are progressive on somatostatin analogues.

Dr. Locke on the ZUMA-6 Trial of Axi-Cel With Atezolizumab for DLBCL

OncLive – Jan. 26
Frederick Locke, MD, Moffitt Cancer Center, discusses the results of the ZUMA-6 trial investigating axicabtagene ciloleucel (axi-cel; KTE-C19) in combination with atezolizumab (Tecentriq) for the treatment of patients with refractory diffuse large B-cell lymphoma (DLBCL).

FDA approves Lutathera for gastroenteropancreatic neuroendocrine tumors

Healio – Jan. 26
“There are very few effective treatment options for patients with inoperable, advanced [gastroenteropancreatic neuroendocrine tumors] who are progressive on somatostatin analogues,” Jonathan Strosberg, MD, associate professor and section head of the neuroendocrine tumor program at Moffitt Cancer Center, said in a manufacturer-issued press release. Also posted to OncLive.com and Targeted Oncology.

Novartis' Lutathera Gets FDA Approval for NET Treatment

Rare Disease Report – Jan. 26
At the 2015 North American Neuroendocrine Tumor Society (NANETS) Annual Symposium, Rare Disease Report spoke with Jonathan R. Strosberg, M.D., medical oncologist, of the Department of Gastrointestinal Oncology at the Moffitt Cancer Center about the Phase 3 NETTER-1 trial.

Are you an older adult going in for surgery? The way you prepare can affect the outcome

TBO.com – Jan. 26
Many seniors aren't adequately prepared for the risks they might face during surgery, which can result in death or serious complications. Some hospitals are working on strategies to change that, including exercise and good diet. [Photo courtesy of Moffitt Cancer Center]

NCI Awards $16M Research Grant to Ponce Health Sciences University and Moffitt Cancer Center

ASCO Post – Jan. 25
Ponce Health Sciences University of Ponce, Puerto Rico, in partnership with the H. Lee Moffitt Cancer Center, Tampa, Florida, has received a grant of $16,000,000 from the National Cancer Institute (NCI).


Please note we cannot guarantee the accuracy or availability of links. The stories belong to the respective publishers, and links may expire. Some news sites require you to register and select a password in order to retrieve articles, but most usually do not charge a fee to retrieve these news stories.